: iStockAnalyst.com Symbols Feed

BioMed News Bytes: CUR, IPXL, QCOR, VRX

Mon, 21 Sep 2009 15:44:46 GMT

On 9/21/09, Neuralstem (AMEX: CUR) ($2.50, +34%, heavy volume) announced that the FDA has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells.[More...]

More Cash, Less Debt = Stock Market Gains?

Thu, 23 Apr 2009 13:41:32 GMT

Today there were a couple of posts about how tech stocks are currently especially attractive because they hold plenty of cash and tend to have little debt. Paul Kedrosky initially caught my eye with his post "Tech Cash is King" which in turn pointed me to a story on Bloomberg by Eric Martin. I ran a screen tonight that looked at both cash and debt. Specifically, I screened for a Price-to-Cash ratio under three, a Debt-to-Equity ratio under three and a Market Cap greater than $2.5 million. Based on these criteria, I obtained a list of 136 stocks. Judging from our list, it is absolutely true that many tech stocks do seem to have lots of cash and little debt. What also became apparent as I went through the list is that there[More...]

Impax Labs: Strong Balance Sheet, Focused R&D

Tue, 21 Apr 2009 03:59:53 GMT

Impax Labs (IPXL) is a small-cap specialty pharma which includes a generic drug division under the Global Pharmaceuticals label and a branded division with R&D operations under the Impax Pharmaceuticals name. The Company recently re-listed on the Nasdaq after previously trading on the pink sheets so many investors are unaware of IPXL and its excellent growth prospects as a smaller version of Teva Pharma (TEVA) with a mix of generic and branded product divisions. Impax differentiates (...)[More...]

FDA, Clinical Trial Calendar Updates: DSCO, IPXL

Mon, 20 Apr 2009 16:32:00 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA (...)[More...]

Generic Cardio Drugs Equal Brands

Tue, 02 Dec 2008 22:24:00 GMT

A meta-analysis review of clinical studies published in peer-reviewed journals was featured today in The Journal of the American Medical Association (JAMA) and concluded that cost-saving generics used to treat a variety of cardiovascular conditions produced equivalent clinical outcomes to higher cost brand name drugs. Despite this clinical evidence, the review notes that a majority (53%) of the 43 editorials analyzed had a negative opinion on generic substitution. While there are currently no ETFs on the market which feature generic drug companies, the ETF Innovators (ETFI)[More...]

Health Cost Containment Index: Expanding Into India, Impax Labs Set to Re-List

Thu, 27 Nov 2008 04:50:00 GMT

The ETF Innovators (ETFI) Global Healthcare Cost Containment Index profiled in the accompanying table is updated and expanded to include more companies from my recent Analysis of Generic Drug Companies from India. The index is structured to include companies with market caps between $150M-$60B, which are involved in producing generic healthcare products such as generic drugs and pharmacy benefit managers which do not have retail store and insurance components. [More...]

Impax to Co-Promote Wyeth's SNRI

Thu, 19 Mar 2009 16:40:11 GMT

Technology based specialty pharmaceutical company Impax Laboratories has said that beginning July 1, 2009, Impax Pharmaceuticals, the company's specialty brand products division will co-promote Wyeth's Pristiq.[More...]

Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009

Tue, 03 Nov 2009 11:47:00 GMT

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported strong growth in revenue, net income and earnings per diluted share in the third quarter 2009.
Total revenue for the third quarter 2009 increased 77% to $64.9 million, compared to the prior year period, due primarily to strong sales of the Company's Global label products.
The strong growth in revenue and gross profit resulted in an increase of $28.3 million in income from operations to $10.2 million, compared to a loss from operations of $18.1 million in the prior year period.

: iStockAnalyst.com Symbols Feed

BioMed News Bytes: CUR, IPXL, QCOR, VRX

More Cash, Less Debt = Stock Market Gains?

Impax Labs: Strong Balance Sheet, Focused R&D

FDA, Clinical Trial Calendar Updates: DSCO, IPXL

Generic Cardio Drugs Equal Brands

Health Cost Containment Index: Expanding Into India, Impax Labs Set to Re-List

Impax to Co-Promote Wyeth's SNRI

Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009

Impax Laboratories Confirms Patent Challenge Relating to TRICOR® 48mg and 145mg Tablets

Impax Laboratories to Host Third Quarter 2009 Earnings Conference Call and Webcast on November 3

Impax Laboratories Settles Pending Litigation for FLOMAX®

Impax Laboratories Commences Shipment of Generic Adderall XR® Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg

Impax Laboratories to Present at the JMP Securities Healthcare Focus Conference

Impax Laboratories Confirms Patent Challenge Relating to ORACEA® Delayed-Release Capsules, 40mg

Impax to Present at the UBS Global Life Sciences Conference

Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease

Impax Laboratories Receives Final FDA Approval for Generic Depakote® Extended-Release 500mg Tablets

Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: OH KIM SUN (10K)

Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: MARKBREITER MICHAEL (10K)

Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: BENET LESLIE Z (10K)

Form 4 FLEMING NIGEL For: May 20 (10K)

Form 4 TERRERI PETER R For: May 20 (10K)

Form 4 KOCH ARTHUR A JR For: May 20 (10K)

Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: NESTOR MICHAEL (10K)

Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: BURR ROBERT L (10K)

Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: HSU LARRY (10K)

Form 4 Mengler Christopher For: May 08 (10K)